LONDON, UK: RTW Venture Fund Limited, a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Artios Pharma Limited (“Artios”) on 27 July 2021 of its completion of a US$153 million Series C financing round.
The Company, alongside other investment vehicles of RTW Investments, LP (the “Investment Manager”), confirms that it participated in the Series C financing round together with other investment firms.
Artios is a UK-based privately held oncology company developing a diverse pipeline of product candidates for the treatment of cancer based on its broad DNA Damage Response (DDR) platform and small molecule drug discovery capabilities. Artios intends to use the proceeds from this financing round to expand its potentially best-in-class ATR inhibitor and first-in-class highly selective Polθ inhibitor programs by enabling clinical development in multiple tumor settings and biological backgrounds of single agent and combination therapies.
Roderick Wong, MD, Managing Partner and Chief Investment Officer of the Investment Manager, said:
“We are excited to support Artios’ novel approach to develop next-generation cancer therapies by leveraging its DDR-based platform. As we grow our Venture Fund and our presence in the UK biotech ecosystem, we are excited to partner with leading local innovators such as Artios.”
The Investment Manager is looking forward to growing the Company’s investment pipeline and updating shareholders on further investments by the Company in due course.